Skip to main content
TipRanks
Go Ultimate75% OFF

Polaryx Therapeutics, Inc. (PLYX) AI Stock Analysis

24 Followers
PLYX

Polaryx Therapeutics, Inc.

(NASDAQ:PLYX)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Polaryx Therapeutics, Inc. (PLYX) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%PLYX-96.20%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$66.30M
Dividend Yield
―
Average Volume (3M)
36.52K
Price to Earnings (P/E)
-7.4
Beta (1Y)
0.35
Revenue Growth
―
EPS Growth
-4.21%
Country
US
Employees
11
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Polaryx Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which co...

Polaryx Therapeutics, Inc. Risk Analysis

Polaryx Therapeutics, Inc. disclosed 81 risk factors in its most recent earnings report. Polaryx Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Polaryx Therapeutics, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PLYX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CUECUE46Neutral$37.62M-0.14-931.52%―401.93%-115.89%
PEPGPEPG44Neutral$272.20M-3.07-58.18%――62.59%
CNTBCNTB43Neutral$40.51M-1.11-171.83%―――
ALDXALDX42Neutral$43.56M-2.63>-0.01%――56.04%
ATRAATRA38Underperform$64.59M-6.2738.79%―-97.39%-155.19%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%PLYXALDXATRACUECNTBPEPGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PLYX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PLYXPolaryx Therapeutics, Inc.1.33-33.67-96.20%
ALDXAldeyra Therapeutics0.84-4.39-83.94%
ATRAAtara Biotherapeutics Inc6.33-7.70-54.88%
CUECue Biopharma4.15-13.56-76.56%
CNTBConnect Biopharma Holdings Ltd.0.59-2.32-79.73%
PEPGPepGen Inc.3.78-2.01-34.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.